NCT05670730 - Study of AOC 1044 in Healthy Adult Volunteers and Participants With Duchenne Muscular Dystrophy (DMD) Mutations Amenable to Exon 44 Skipping | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 9, 2022

Primary Completion Date

November 25, 2024

Study Completion Date

November 25, 2024

Conditions

Duchenne Muscular DystrophyExon 44

Interventions

DRUG

AOC 1044

AOC 1044 will be administered via intravenous (IV) infusion

DRUG

Placebo

Placebo will be administered via intravenous (IV) infusion.

Trial Locations (10)

Rare Disease Research NC, Hillsborough

Rare Disease Research - Atlanta, Atlanta

Abigail Research Institute at Nationwide Children's Hospital, Columbus

University of Iowa, Iowa City

Gillette Children's, Saint Paul

Arkansas Children's, Little Rock

Worldwide Clinical Trials (Part A only), San Antonio

UCSD, La Jolla

Stanford University, Palo Alto

University of Massachusetts Chan Medical School, Worcester